2019 Q1 Form 10-Q Financial Statement

#000156459019002298 Filed on February 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $680.0K $779.0K $1.153M
YoY Change -38.46% -32.44% 0.17%
Cost Of Revenue $100.0K $100.0K $200.0K
YoY Change -64.29% -50.0% -4.76%
Gross Profit $580.0K $679.0K $953.0K
YoY Change -29.27% -28.75% 1.38%
Gross Profit Margin 85.29% 87.16% 82.65%
Selling, General & Admin $3.340M $3.387M $4.870M
YoY Change -24.6% -30.45% -12.25%
% of Gross Profit 575.86% 498.82% 511.02%
Research & Development $4.400M $3.782M $4.010M
YoY Change 10.83% -5.69% -20.12%
% of Gross Profit 758.62% 557.0% 420.78%
Depreciation & Amortization $160.0K $250.0K $310.0K
YoY Change -48.39% -19.35% -3.13%
% of Gross Profit 27.59% 36.82% 32.53%
Operating Expenses $7.740M $7.169M $8.870M
YoY Change -7.97% -19.18% -16.08%
Operating Profit -$7.160M -$6.526M -$7.917M
YoY Change -5.67% -17.57% -17.79%
Interest Expense $180.0K $190.0K $120.0K
YoY Change 28.57% 58.33% 140.0%
% of Operating Profit
Other Income/Expense, Net $127.0K
YoY Change
Pretax Income -$6.980M -$6.400M -$7.790M
YoY Change -6.31% -17.84% -18.68%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.980M -$6.399M -$7.791M
YoY Change -6.3% -17.87% -18.68%
Net Earnings / Revenue -1026.47% -821.44% -675.72%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.167M -$1.102M -$1.451M
COMMON SHARES
Basic Shares Outstanding 119.5M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.48M $35.22M $47.34M
YoY Change -16.58% -25.6% -32.37%
Cash & Equivalents $36.48M $35.35M $47.34M
Short-Term Investments
Other Short-Term Assets $1.050M $530.0K $890.0K
YoY Change -9.48% -40.45% 50.85%
Inventory $490.0K $1.050M $610.0K
Prepaid Expenses
Receivables $503.0K $550.0K $1.170M
Other Receivables $60.00K $120.0K $260.0K
Total Short-Term Assets $38.57M $37.47M $50.27M
YoY Change -17.51% -25.46% -30.12%
LONG-TERM ASSETS
Property, Plant & Equipment $1.832M $1.950M $2.980M
YoY Change -34.29% -34.56% -24.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $138.0K $270.0K $310.0K
YoY Change -9.21% -12.9% 24.0%
Total Long-Term Assets $2.049M $2.220M $3.280M
YoY Change -33.19% -32.32% -21.72%
TOTAL ASSETS
Total Short-Term Assets $38.57M $37.47M $50.27M
Total Long-Term Assets $2.049M $2.220M $3.280M
Total Assets $40.62M $39.69M $53.55M
YoY Change -18.47% -25.88% -29.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $628.0K $650.0K $450.0K
YoY Change 35.34% 44.44% -37.5%
Accrued Expenses $2.549M $2.180M $2.990M
YoY Change -23.71% -27.09% -3.24%
Deferred Revenue $525.0K $580.0K
YoY Change -21.41%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.737M $3.410M $4.300M
YoY Change -19.77% -20.7% -3.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $590.0K $600.0K $660.0K
YoY Change 1.72% -9.09% -16.46%
Total Long-Term Liabilities $590.0K $600.0K $660.0K
YoY Change 1.72% -9.09% -16.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.737M $3.410M $4.300M
Total Long-Term Liabilities $590.0K $600.0K $660.0K
Total Liabilities $4.325M $4.010M $4.950M
YoY Change -17.48% -18.99% -5.35%
SHAREHOLDERS EQUITY
Retained Earnings -$260.8M
YoY Change 11.38%
Common Stock $297.1M
YoY Change 6.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.30M $35.68M $48.60M
YoY Change
Total Liabilities & Shareholders Equity $40.62M $39.69M $53.55M
YoY Change -18.47% -25.88% -29.66%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$6.980M -$6.399M -$7.791M
YoY Change -6.3% -17.87% -18.68%
Depreciation, Depletion And Amortization $160.0K $250.0K $310.0K
YoY Change -48.39% -19.35% -3.13%
Cash From Operating Activities -$5.080M -$3.950M -$6.450M
YoY Change -9.45% -38.76% -8.51%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$30.00K -$30.00K
YoY Change -71.43% 0.0% -95.08%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$50.00K -$20.00K -$30.00K
YoY Change -61.54% -33.33% -95.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.320M 1.850M 3.090M
YoY Change 199.53% -40.13% -88.11%
NET CHANGE
Cash From Operating Activities -5.080M -3.950M -6.450M
Cash From Investing Activities -50.00K -20.00K -30.00K
Cash From Financing Activities 6.320M 1.850M 3.090M
Net Change In Cash 1.190M -2.120M -3.390M
YoY Change -132.78% -37.46% -118.56%
FREE CASH FLOW
Cash From Operating Activities -$5.080M -$3.950M -$6.450M
Capital Expenditures -$40.00K -$30.00K -$30.00K
Free Cash Flow -$5.040M -$3.920M -$6.420M
YoY Change -7.86% -38.94% -0.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
127000
CY2018Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
127000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
747000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
185000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119493341
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43726000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1153000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
883000
CY2018Q4 us-gaap Grants Receivable
GrantsReceivable
124000
CY2018Q1 us-gaap Grants Receivable
GrantsReceivable
145000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
580000
CY2018Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
668000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
27000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2018Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
600000
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
564000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2411000
CY2018Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
136000
CY2017Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
192000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
381000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35675000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3911000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
527000
onvo Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
260000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-253000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-719000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1293000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
260000
onvo Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-113000
CY2017Q4 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-63000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
44586000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
127000
onvo Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
6915000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62878000
onvo Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
-135000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
74000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
826000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7995000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8502000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43853000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15413000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47338000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3911000
us-gaap Profit Loss
ProfitLoss
-27354000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-63000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
824000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
962000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5600000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-336000
onvo Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-21000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
207000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-637000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
183000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1185000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-107000
onvo Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-122000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
70000
onvo Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6916000
onvo Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
7243000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
136000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6830000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
us-gaap Income Taxes Paid
IncomeTaxesPaid
23000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note<font style="font-weight:normal;">&#160;</font>1. Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of&#160;operations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organovo Holdings, Inc.,&#160;(&#8220;Organovo Holdings,&#8221; and collectively with its subsidiaries, &#8220;the&#160;Company&#8221;) is&#160;a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on its revolutionary ability to 3D bioprint liver tissues that emulate human biology and disease. The Company is developing its <font style="font-style:italic;">in vivo</font> liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company&#8217;s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (&#8220;A1AT&#8221;), received the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) orphan drug designation in December 2017. The Company&#8217;s first Investigational New Drug Application (&#8220;IND&#8221;) filing is targeted for calendar-year 2020. Organovo Holdings is also capitalizing on its foundational ability to characterize highly specialized human cells and to build robust, functional human tissues by creating a range of novel <font style="font-style:italic;">in vitro</font> disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;) and non-alcoholic steatohepatitis (&#8220;NASH&#8221;) conditions. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where specifically noted or the context otherwise requires, references to &#8220;Organovo Holdings,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo U.K., Ltd. In March 2018, the U.K. operations were combined with Organovo, Inc.&#8217;s operations.</p>
us-gaap Cost Of Revenue
CostOfRevenue
400000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
136000
CY2018Q4 us-gaap Cost Of Revenue
CostOfRevenue
100000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification of prior year presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.</p>
CY2017Q4 us-gaap Cost Of Revenue
CostOfRevenue
200000
us-gaap Cost Of Revenue
CostOfRevenue
700000
CY2018Q4 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2017Q4 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14000000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8315000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7307
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8071
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7299
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7686
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0279
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0215
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.67
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.73
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10132312
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8024194
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4496763
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
622192
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13037551
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4481218
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.01
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.21
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.08
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.45
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.06
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
591082
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
561591
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M18D
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29290172
onvo Operating Leases Monthly Rent Expense
OperatingLeasesMonthlyRentExpense
120000
CY2018Q4 us-gaap Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
0.03
onvo Office Space Area Under Lease Agreement
OfficeSpaceAreaUnderLeaseAgreement
45580
CY2018Q4 onvo Landlord Funded Tenant Improvements
LandlordFundedTenantImprovements
500000
CY2018Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
onvo Leasehold Improvements Funded By Lease Incentive
LeaseholdImprovementsFundedByLeaseIncentive
518000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
264222000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1073027000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1104070000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1145861000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1183092000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1732566000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6502838000

Files In Submission

Name View Source Status
0001564590-19-002298-index-headers.html Edgar Link pending
0001564590-19-002298-index.html Edgar Link pending
0001564590-19-002298.txt Edgar Link pending
0001564590-19-002298-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
onvo-10q_20181231.htm Edgar Link pending
onvo-20181231.xml Edgar Link completed
onvo-20181231.xsd Edgar Link pending
onvo-20181231_cal.xml Edgar Link unprocessable
onvo-20181231_def.xml Edgar Link unprocessable
onvo-20181231_lab.xml Edgar Link unprocessable
onvo-20181231_pre.xml Edgar Link unprocessable
onvo-ex311_8.htm Edgar Link pending
onvo-ex312_6.htm Edgar Link pending
onvo-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending